THPP-1
CAS No. 1257051-63-0
THPP-1( —— )
Catalog No. M22050 CAS No. 1257051-63-0
THPP-1 is a potent and orally bioavailable inhibitor of PDE10A(Ki of 1 nM and 1.3 nM for human and rat PDE10A, respectively).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 40 | Get Quote |
|
| 5MG | 65 | Get Quote |
|
| 10MG | 110 | Get Quote |
|
| 25MG | 237 | Get Quote |
|
| 50MG | 402 | Get Quote |
|
| 100MG | 593 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameTHPP-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionTHPP-1 is a potent and orally bioavailable inhibitor of PDE10A(Ki of 1 nM and 1.3 nM for human and rat PDE10A, respectively).
-
DescriptionTHPP-1 is a potent and orally bioavailable inhibitor of PDE10A(Ki of 1 nM and 1.3 nM for human and rat PDE10A, respectively). Consistent with rodent data, both THPP-1 and risperidone significantly attenuated the stimulant effects in SIMA when administered alone, though some differences were noted.?Combination therapy with a low dose of risperidone produced significantly more robust effects.?THPP-1 and risperidone also produced a marked reduction of wake cycle time and gamma frequency power in EEG.?However, THPP-1 differed from risperidone by reducing spectral power of lower frequencies.
-
In Vitro——
-
In VivoTHPP-1 (0.1-1.0 mg/kg, p.o.) shows novel object recognition in rats.THPP-1 (p.o., 1-30 mg/kg) dose-dependently increases phosphorylation of GluR1 S845 in the rat striatum whereas the total levels of GluR1 in the striatum are not affected. Administration of THPP-1 also results in an associated increase in the pGluR1/GluR1 ratios at all doses examined in this study.THPP-1 (1, 3, 10 mg/kg, p.o.) significantly attenuated the stimulant effects in stimulant-induced motor activity (SIMA) in monkey. Animal Model:Male Wistar Hannover rats ranging from 200 to 300 g.Dosage:0.1-1.0 mg/kg.Administration:P.O.Result:Showed novel object recognition.Animal Model:Eleven monkeys were surgically implanted with subcutaneous telemetric devices to permit the simultaneous recording of electrocorticogram (ECoG), electrooculogram (EOG), and electromyogram (EMG) activit Dosage:1, 3, 10 mg/kg. Administration:P.O.Result:Significantly attenuated the stimulant effects in SIMA.Animal Model:Male Wistar Hannover rats ranging from 200 to 300 g.Dosage:1-30 mg/kg.Administration:P.O. (10% Tween 80/90% water) 2 h prior to tissue collection (Pharmacokinetic Analysis).Result:Dose-dependently increases phosphorylation of GluR1 S845.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetPDE
-
RecptorPDE10A
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1257051-63-0
-
Formula Weight464.9
-
Molecular FormulaC23H21ClN6O3
-
Purity>98% (HPLC)
-
SolubilityDMSO:31 mg/mL (66.68 mM; Need ultrasonic)
-
SMILESCOCCOC1=C2CN(CCC2=NC(=N1)C1=CC=C(Cl)N=C1)C(=O)C1=C2C=CC=CN2C=N1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Vardigan JD, et al. Behavioral and qEEG effects of the PDE10A inhibitor THPP-1 in a novel rhesus model of antipsychotic activity. Psychopharmacology (Berl). 2016 Jul;233(13):2441-50.
molnova catalog
related products
-
HA-155
HA155 is a boronic acid-based compound, inhibiting ATX with IC50 of 5.7 nM by selectively binding to its catalytic threonine.
-
ONO-8430506
ONO-8430506 is an orally available, potent autotaxin (ATX)/ENPP2 inhibitor (IC90: 100 nM) that inhibits ATX activity in mouse plasma.
-
(+)-Medioresinol Di-...
(+)-Medioresinol Di-O-β-D-glucopyranoside has strong inhibitory activity of cyclic AMP phosphodiesterase.
Cart
sales@molnova.com